Strategy

Vectura’s strategy is to target the treatment of diseases associated with the lungs. 

The Group has a broad clinical portfolio that combines valuable mid and late-stage programmes with high-potential, earlier-stage opportunities and has a wide range of device and formulation technologies addressing large and fast-growing market sectors.

The respiratory development pipeline comprises inhaled formulations of both branded and generic products for the treatment of asthma, chronic obstructive pulmonary disease and cystic fibrosis.

Vectura seeks value from its other pipeline products through out-licensing

• Vectura has developed therapies for indications such as Parkinson’s disease, which it is actively seeking to out-license.

Vectura’s goal is to be a cash-generative business that creates value for its shareholders through:

• its intellectual property and expertise in inhaled product development, which allows Vectura to:
  • out-license products to major pharmaceutical companies in return for revenues from milestones and royalties
  • develop or co-develop specialty products to regulatory approval or beyond, to capture maximum value from licensing at a later stage of development or from sales revenues
• entering into technology collaborations with pharmaceutical company partners to exploit both the generic and branded markets for the joint development of high-value inhaled product opportunities, and
• continuing to build its franchise through internal innovation as well as exploring opportunities for the acquisition of products, technologies or businesses that support these goals.